U.S. regulators on Friday approved AbbVie Inc.’s new multidrug regimen for hepatitis C, the latest in a wave of new medicines that is transforming treatment of the liver disease.
WSJ.com: What's News US, Wall Street Journal
Fri, 12/19/2014 - 1:09pm
U.S. regulators on Friday approved AbbVie Inc.’s new multidrug regimen for hepatitis C, the latest in a wave of new medicines that is transforming treatment of the liver disease.